繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

抗癌药物NVL-520的1/2期试验中的第一例患者

2022-01-07 20:00

06:59 AM EST, 01/07/2022 (MT Newswires) -- Nuvalent (NUVL) said Friday that the first patient has been dosed in the phase 1/2 clinical trial evaluating its NVL-520 lead product candidate in patients with advanced ROS1-positive non-small cell lung cancer and other advanced solid tumors.

According to the company, enrollment for the trial's phase-one dose-escalation portion is ongoing, with a view to evaluate the product candidate's safety and tolerability, and determine the recommended dosage for the phase-two trial.

Nuvalent said it also continues to advance the development of another drug, NVL-655, as a potential treatment for patients with ALK-positive non-small cell lung cancer.

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。